Matthew Porteus, MD, PhD, highlighted preclinical advances in automated stem cell gene editing that could improve manufacturing scalability while supporting the development of next-generation genetic medicines.
|Articles|November 1, 2021
Daily Medication Pearl: Pembrolizumab (Keytruda)
Author(s)Saro Arakelians, PharmD
Pembrolizumab (Keytruda) can be used for multiple cancer types, including melanoma, non-small cell lung cancer, and head and neck squamous cell cancer.
Advertisement
Medication Pearl of the Day: Pembrolizumab (Keytruda)
Indication: Pembrolizumab can be used for melanoma, non-small cell lung cancer, head and neck squamous cell cancer, Hodgkin lymphoma, urothelial carcinoma, gastric cancer, cervical cancer, renal cell carcinoma, esophageal cancer, hepatocellular cancer, endometrial cancer, cutaneous squamous cell carcinoma and others.
Insight:
- Dosing: May vary per each indication, however it’s usually 200 mg every 3 weeks or 400 mg every 6 weeks.
- Dosage form: Injection 100 mg/4 mL (25 mg/mL) solution in a single-dose vial.
- Adverse events: May include pruritis, diarrhea, constipation, pain, alopecia, neutropenia, headache, weight loss, vomiting, and arthralgia.
- Mechanism of action: Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with programmed death-ligand 1 (PD-L1) and PD-L2, releasing programmed cell death protein 1 (PD-1) pathway-mediated inhibition of the immune response, including the anti-tumor immune response.
- Manufacturer: Merck
Reference:
Advertisement
Related to this article
Payer requirements, prescriber habits, and operational realities ultimately determine which ICI patients receive.
If approved, the combination would be the first chemotherapy-free, Bruton tyrosine kinase inhibitor–based regimen for adults with newly diagnosed mantle cell lymphoma (MCL).
Manufacturing delays, financial barriers, and complex care coordination can limit access to gene therapy, emphasizing the need for patient-centered programs and long-term follow-up.
Experts highlighted how Diamond-Blackfan anemia illustrates the scientific, financial, and manufacturing challenges that can prevent promising gene therapies for ultra-rare diseases from reaching patients.
Experts highlighted recent gene therapy approvals for inherited immune disorders while addressing ongoing challenges in manufacturing, long-term safety, and patient access.
At the 2026 ASTCT Gene Therapy Summit, experts highlighted how chronic pain, psychological challenges, and neurologic complications may persist despite successful treatment.
Pharmacists navigate BCMA therapy sequencing in relapsed/refractory multiple myeloma, weighing linvoseltamab logistics, community readiness, safety monitoring, and smoother care transitions.
Advertisement
Advertisement
Trending on Pharmacy Times
1
What Drives First-Line Immunotherapy Selection in NSCLC? Data, Payers, and Habit
2
FDA Grants Priority Review to Zanubrutinib Plus Rituximab for Previously Untreated MCL
3
AHA 2026: Insights on Oral PCSK9, Survodutide, and HF Care Come to Chicago
4
Amivantamab Becomes First FDA-Approved Therapy in 10 Years for Pretreated Recurrent or Metastatic HNSCC
5